Notas do episódio
The baseline is completely broken and the iteration process is blind.
FDA’s August 21, 2026 warning letter to Pensar Medical LLC illustrates a failure that goes well beyond incomplete documentation.
The underlying risk-management foundation was weak. Risk-control verification remained incomplete for critical areas, and FDA reportedly found no design, process, or use-related FMEAs for the WoundPro product line.
At the same time, key QMS processes were also failing.
Key highlights covered in the audio:
* Risk analysis was incomplete or missing. Critical risk controls remained unverified, and…
Site: naveenagarwalphd.substack.com

